One brand. No moat. Tons of competition. That's why I lost interest in Bare Escentuals'
Net income increased 22% to $24.7 million, or $0.26 per share. Revenue increased 11.6% to $138.6 million. Those figures might not sound too bad, but bear in mind that Bare Escentuals gave slightly less rosy guidance for the year than Wall Street was expecting.
There may be other troubling signs. Bare Escentuals' inventory surged by 45% on a year-over-year basis, surpassing its sales increase. Accounts receivable also increased 31%. In the conference call, management said the inventory growth was because it brought kit assembly operations and fulfillment in-house, which it says will provide "greater quality and flexibility at a lower overall cost." It also said the growth in accounts receivable reflected growth in the wholesale channel.
Of course, a major inventory buildup evident at Crocs
Last but not least, Bare Escentuals' significant debt load bugs me. It has nearly $250 million in debt, and just $31 million in cash.
Meanwhile, competition is stepping up at a rapid pace. I noted months ago that you could find similar products at the drugstore (such as L'Oreal's "Bare Naturale," Revlon's
I recently visited Prescriptives' website (one of Estee Lauder's
Add in the rough consumer climate, and I think it's a pretty terrible time to invest in an upstart makeup brand that was born of infomercials, has attracted all manner of copycats, and may very well prove to be a makeup fad. Given all these factors, even with today's price drop, Bare Escentuals' stock doesn't look like a beautiful -- or particularly safe -- long-term stock idea to me.
Crocs is a Motley Fool Hidden Gems Pay Dirt pick. Johnson & Johnson is a Motley Fool Income Investor recommendation. Try any of our Foolish newsletters today, free for 30 days.